Sharklet Technologies, a Aurora, Colo.-based biotechnology company that develops bacteria-inhibiting micro-texture surface technology, has received $2m in funding.
Altria Ventures, the venture capital investment arm of Altria Group, will acquire a 12.5% stake in the company.
Led by Mark Spiecker, CEO, Sharklet Technologies has developed Sharklet™, a surface technology that is designed to control bacteria including Staph a., MRSA, VRE, E. coli and a host of others. Sharklet™ is suited for commercial, healthcare, food service and laboratory environments where bacterial inhibition is desired to help protect human health.
The company is based at the Bioscience Park Center, an incubator in the Fitzsimons Life Science District adjacent to the renowned Anschutz Medical Campus in Aurora, Colo.